Reduction of neointimal hyperplasia in porcine coronary arteries by 2-deoxy-D-glucose.
BACKGROUND
The drug eluting stents have been shown to play a substantial role in preventing in-stent restenosis. This study was initiated to determine the efficacy of 2-deoxy-D-glucose (2-DG) in an in-stent restenosis model for reducing neointimal hyperplasia after coronary stent placement.


METHODS
In a porcine overstretch model, three kinds of stents were investigated (n = 12 per group): bare metal stents (BMS), rapamycin-eluted stents (RES), and BMS after intracoronary short-term application of 2-DG (DGS). After 42 days histomorphometric and histopathological analyses were performed.


RESULTS
Neointimal thickness (BMS: 0.38 +/- 0.08, RES: 0.24 +/- 0.11, DGS: 0.15 +/- 0.01), area stenosis (BMS: 47.39 +/- 2.76, RES: 32.2 +/- 2.08, DGS: 29.30 +/- 2.98) did not differ after 42 days between the RES and DGS but were significantly lower as compared to BMS only. Lumen area (BMS: 3.15 +/- 1.53, RES: 4.37 +/- 1.72, DGS: 4.77 +/- 2.14) was significantly higher in the DGS group in comparison to the BMS group. The calculated injury and inflammation scores were similar and re-endothelialization was confirmed in all groups.


CONCLUSIONS
This study could demonstrate that in porcine stent model neointimal hyperplasia and re-endothelialization after application of 2-DG are comparable to those seen in RES. Thus, 2-DG might be a promising clinical application for coronary stent coating.
Nef
Holger M
HM
Department of Cardiology, Kerckhoff Heart Center, Bad Nauheim, Germany. h.nef@kerckhoff-fgi.de
Möllmann
Helge
H
Joseph
Astrid
A
Troidl
Christian
C
Voss
Sandra
S
Rauch
Maximilian
M
Kinscherf
Ralf
R
Vogt
Achim
A
Weber
Michael
M
Hamm
Christian W
CW
Elsässer
Albrecht
A
D000818:Animals; D000963:Antimetabolites / Q000008:administration & dosage; D023903:Coronary Restenosis / Q000209:etiology* / Q000473:pathology / Q000517:prevention & control*; D003847:Deoxyglucose / Q000008:administration & dosage*; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D006083:Graft Occlusion, Vascular / Q000209:etiology* / Q000473:pathology / Q000517:prevention & control*; D008297:Male; D013552:Swine; D016896:Treatment Outcome
D000963:Antimetabolites; D003847:Deoxyglucose